Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefepime + colistin is a combination of two antibiotics used primarily for the treatment of severe infections caused by multidrug-resistant Gram-negative bacteria, including carbapenem-resistant organisms. Cefepime is a fourth-generation cephalosporin (beta-lactam) antibiotic that acts by inhibiting penicillin-binding proteins (PBPs), disrupting bacterial cell wall synthesis and leading to cell lysis and death. Colistin (also known as polymyxin E) is a polymyxin antibiotic that disrupts the outer and inner membranes of Gram-negative bacteria by binding to lipopolysaccharides, displacing divalent cations, and increasing membrane permeability, resulting in bacterial cell death. The combination is often reserved for critically ill patients with limited therapeutic options due to resistance patterns[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefepime + colistin.